U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C8H11N3O3S
Molecular Weight 229.256
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LAMIVUDINE

SMILES

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

InChIKey=JTEGQNOMFQHVDC-NKWVEPMBSA-N
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

HIDE SMILES / InChI
Molecular Formula C8H11N3O3S
Molecular Weight 229.256
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00709 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2df7349c-f5d7-47b5-d29b-1b6b31985591

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. The most common reported adverse reactions in adults are headache, nausea, malaise and fatigue. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.

CNS Activity

CNS Penetrant
2432
Curator's Comment: Known to be CNS penetrant in rat, guinea pig. Human data not available. http://www.ncbi.nlm.nih.gov/pubmed/9593963 http://www.ncbi.nlm.nih.gov/pubmed/18042828 http://www.ncbi.nlm.nih.gov/pubmed/12766261

Originator

Approval Year

1995
184
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
 2.0 nM [IC50]
Inhibitor
8146
 3.3 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
EPIVIR

Approved Use

EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Launch Date

1.10108161E12
Primary
Approved
8307
EPIVIR

Approved Use

EPIVIR-HBV is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation

Launch Date

1.10108161E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.3 μg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29150845
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LAMIVUDINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.4 μg/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf
150 mg 2 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LAMIVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
12.4 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29150845
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LAMIVUDINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.53 μg × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf
150 mg 2 times / day multiple, oral
dose: 150 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LAMIVUDINE unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.9 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29150845
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
LAMIVUDINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Other AEs: Malaise and fatigue, Ear, nose and throat infection...
Other AEs:
Malaise and fatigue (25%)
Ear, nose and throat infection (17%)
Cough (8%)
Headache (17%)
Nausea and vomiting (8%)
Ear, nose and throat infection (8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Other AEs: Coughing, Diarrhea...
Other AEs:
Coughing (6 patients)
Diarrhea (9 patients)
Abdominal discomfort (2 patients)
Nausea and vomiting (1 patient)
Malaise and fatigue (6 patients)
Headache (6 patients)
Disorder sleep (4 patients)
Cognitive disorders (2 patients)
Oral ulceration (2 patients)
Oral lesion (2 patients)
Muscle pain (3 patients)
Arthralgia (1 patient)
Temperature regulation disorder (2 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Other AEs: Malaise and fatigue, Cough...
Other AEs:
Malaise and fatigue (27%)
Cough (27%)
Temperature regulation disorder NOS (27%)
Nausea and vomiting (9%)
Ear, nose and throat infection (18%)
Ear disorder (9%)
Pharyngitis (18%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Other AEs: Headache, Malaise and fatigue...
Other AEs:
Headache (35%)
Malaise and fatigue (27%)
Chills & fever (10%)
Nausea (33%)
Diarrhea (18%)
Nausea and vomiting (13%)
Decreased appetite (10%)
Abdominal pain (9%)
Abdominal cramps (6%)
Dyspepsia (5%)
Neuropathy (12%)
Insomnia disorder (11%)
Dizziness (10%)
Depressive disorders (9%)
Nasal disorders NEC (20%)
Cough (18%)
Skin rash (9%)
Musculoskeletal pain (12%)
Myalgia (8%)
Arthralgia (5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Ear, nose and throat infection 17%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Headache 17%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Malaise and fatigue 25%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Cough 8%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Ear, nose and throat infection 8%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Nausea and vomiting 8%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 14.6
n = 12
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 14.6
Sex: M+F
Population Size: 12
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Arthralgia 1 patient
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Nausea and vomiting 1 patient
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Abdominal discomfort 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Cognitive disorders 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Oral lesion 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Oral ulceration 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Temperature regulation disorder 2 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Muscle pain 3 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Disorder sleep 4 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Coughing 6 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Headache 6 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Malaise and fatigue 6 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Diarrhea 9 patients
10 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 10 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
unhealthy, 37 years (range: 23-63 years)
n = 14
Health Status: unhealthy
Condition: HIV infection
Age Group: 37 years (range: 23-63 years)
Population Size: 14
Sources:
https://pubmed.ncbi.nlm.nih.gov/7751691/
Ear, nose and throat infection 18%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Pharyngitis 18%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Cough 27%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Malaise and fatigue 27%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Temperature regulation disorder NOS 27%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Ear disorder 9%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Nausea and vomiting 9%
4 mg/kg 2 times / day multiple, oral
Highest studied dose
Dose: 4 mg/kg, 2 times / day
Route: oral
Route: multiple
Dose: 4 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
unhealthy, 7.6
n = 11
Health Status: unhealthy
Condition: Chronic hepatitis B
Age Group: 7.6
Sex: M+F
Population Size: 11
Sources:
https://pubmed.ncbi.nlm.nih.gov/10681323/
Chills & fever 10%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Decreased appetite 10%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Dizziness 10%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Insomnia disorder 11%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Musculoskeletal pain 12%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Neuropathy 12%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Nausea and vomiting 13%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Cough 18%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Diarrhea 18%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Nasal disorders NEC 20%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Malaise and fatigue 27%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Nausea 33%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Headache 35%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Arthralgia 5%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Dyspepsia 5%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Abdominal cramps 6%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Myalgia 8%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Abdominal pain 9%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Depressive disorders 9%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Skin rash 9%
150 mg 1 times / day multiple, oral
Recommended
Dose: 150 mg, 1 times / day
Route: oral
Route: multiple
Dose: 150 mg, 1 times / day
Co-administed with::
zidovudine(200 mg; 3/day)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
unhealthy
n = 251
Health Status: unhealthy
Condition: HIV-1 infection
Population Size: 251
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1532
inhibitor
1695
inhibitor
1789

OverviewOther

Other InhibitorOther SubstrateOther Inducer
OATP1B1
770

OATP1B3
691

MATE2
259

OCT3
143

BCRP
678

P-gp
1401

OCT1
498

OCT2
630
MATE1
131

MATE2
93

OCT1
317

OCT2
336

P-gp
1491

BCRP
545

CYP
252
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C9
1747
 no
CYP2D6
1826
 no
CYP3A4
1857
 no
MATE2
259
 no
OATP1B1
785
 no
OATP1B3
700
 no
BCRP
751
 weak to no
OCT3
143
 weak to no
P-gp
1588
 weak to no
OCT1
513
 yes
OCT2
631
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
252
 not signifiicant
BCRP
545
 yes
MATE1
131
 yes
MATE2
93
 yes
OCT1
317
 yes
OCT2
336
 yes
P-gp
1491
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:63577
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63577
ChemicalBook
CB1290608
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1290608
MolPort
MolPort-002-507-347
https://www.molport.com/shop/molecule-link/MolPort-002-507-347
Selleck Chemicals
Lamivudine(Epivir)
http://www.selleckchem.com/products/Lamivudine(Epivir).html
ZINC
ZINC000000012346
http://zinc15.docking.org/substances/ZINC000000012346
eMolecules
1987423
https://www.emolecules.com/cgi-bin/more?vid=1987423
eMolecules
2726078
https://www.emolecules.com/cgi-bin/more?vid=2726078
eMolecules
31588897
https://www.emolecules.com/cgi-bin/more?vid=31588897
PubMed

PubMed

TitleDatePubMed
Disappearance of hepatitis B virus core deletion mutants and successful combined kidney/liver transplantation in a patient treated with lamivudine.
1999
Anti-HIV-1 activities of 1,3-dioxolane guanine and 2,6-diaminopurine dioxolane.
1999 Apr-May
Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.
1999 Aug 15
Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.
1999 Jun
Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin.
1999 Nov
Mechanism of action and in vitro activity of 1',3'-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants.
1999 Oct
Inhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces species.
1999 Oct
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.
1999 Oct 1
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
1999 Sep
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.
2000
Additional interferon alpha for lamivudine resistant hepatitis B infection after liver transplantation: a preliminary report.
2000 Apr 27
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.
2000 Aug
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
2000 Aug
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.
2000 Jan 28
Synthesis and anti-HIV evaluation of new 2',3'-dideoxy-3'-thiacytidine prodrugs.
2000 Jul
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
2000 Jul
Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
2000 Jul
Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
2000 Jul
Management of hepatitis B in China.
2000 Jul
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
2000 Jul 4
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
2000 Jun 10
Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy.
2000 Jun 16
Synthesis and antiviral evaluation of some beta-L-2', 3'-dideoxy-5-chloropyrimidine nucleosides and pronucleotides.
2000 Mar
Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.
2000 May
Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.
2000 Nov
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
2000 Nov
Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
2000 Nov
Leucocytoclastic vasculitis and indinavir.
2000 Nov
Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus.
2000 Nov
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
2000 Oct
Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.
2000 Sep 15
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.
2001 Apr
Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature.
2001 Aug
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.
2001 Jun
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.
2001 Jun 29
Efavirenz-induced acute eosinophilic hepatitis.
2001 May
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.
2001 May
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
2001 Sep 1
Patents

Patents

05905082
3
US5047407
4

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Pediatric dose should be calculated on body weight (kg) and should not exceed 300 mg daily. Dosage of this product is for HIV-1 and not for HBV
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 17 18:06:57 UTC 2022
Edited
by admin
on Sat Dec 17 18:06:57 UTC 2022
Record UNII
2T8Q726O95
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LAMIVUDINE
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN   INN  
Official Name English
TEMIXYS COMPONENT LAMIVUDINE
Common Name English
EPIVIR
Brand Name English
LAMIVUDINE [EP MONOGRAPH]
Common Name English
4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]
Systematic Name English
EMTRICITABINE IMPURITY C [WHO-IP]
Common Name English
KIVEXA COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINUM [WHO-IP LATIN]
Common Name English
GR-109714X
Code English
COMBIVIR COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE
Brand Name English
TRIZIVIR COMPONENT LAMIVUDINE
Brand Name English
VIROLAM
Common Name English
LAMIVUDINE [WHO-IP]
Common Name English
NSC-760061
Code English
LAMIVUDINE [USP-RS]
Common Name English
3TC
Code English
TELURA COMPONENT OF LAMIVUDINE
Common Name English
LAMIVUDINE COMPONENT OF TRIUMEQ
Brand Name English
LAMIVUDINE COMPONENT OF TRIZIVIR
Brand Name English
LAMIVUDINE COMPONENT OF DUTREBIS
Brand Name English
GR 109714X
Code English
LAMIVUDINE COMPONENT OF DELSTRIGO
Brand Name English
LAMIVUDINE COMPONENT OF COMBIVIR
Common Name English
DELSTRIGO COMPONENT LAMIVUDINE
Brand Name English
LAMIVUDINE COMPONENT OF TEMIXYS
Common Name English
LAMIVUDINE [ORANGE BOOK]
Common Name English
Lamivudine [WHO-DD]
Common Name English
LAMIVUDINE TEVA
Brand Name English
lamivudine [INN]
Common Name English
LAMIVUDINE [EP IMPURITY]
Common Name English
ZEFFIX
Brand Name English
LAMIVUDINE [HSDB]
Common Name English
LAMIVUDINE [JAN]
Common Name English
LAMIVUDINE TEVA PHARMA B.V.
Brand Name English
(-)-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE
Systematic Name English
LAMIVUDINE [EMA EPAR]
Common Name English
LAMIVUDINE COMPONENT OF EPZICOM
Common Name English
BCH 189, (-)-
Code English
TRIUMEQ COMPONENT LAMIVUDINE
Brand Name English
LAMIVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA
Brand Name English
LAMIVUDINE [MART.]
Common Name English
EPZICOM COMPONENT LAMIVUDINE
Common Name English
LAMIVUDINE [USAN]
Common Name English
LAMIVUDINE [VANDF]
Common Name English
2(1H)-PYRIMIDINONE, 4-AMINO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-, (2R-CIS)-
Common Name English
LAMIVUDINE [USP MONOGRAPH]
Common Name English
LAMIVUDINE [MI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000175462
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-VATC QJ05AR04
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR05
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-VATC QJ05AR02
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
NCI_THESAURUS C97452
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS LAMIVUDINE TEVA PHARMA B.V. (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-VATC QJ05AR05
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS KIVEXA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-VATC QJ05AR11
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR02
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR11
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/ZID)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR16
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
NDF-RT N0000175459
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
NDF-RT N0000175656
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
NDF-RT N0000175459
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS ZEFFIX (AUTHORIZED: HEPTATIS B, CHRONIC)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR24
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR12
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR07
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
NDF-RT N0000009947
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS EPIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/NEV/STA)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
LIVERTOX NBK548553
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR01
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR13
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AR04
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS TRIUMEQ (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-VATC QJ05AR01
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS LAMIVUDINE/ZIDOVUDINE TEVA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
NDF-RT N0000175459
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ATC J05AF05
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-VATC QJ05AR07
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS COMBIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS TRIZIVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LAM/ZID)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS LAMIVUDINE TEVA (AUTHORIZED: HEPATITIS B, CHRONIC)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
EMA ASSESSMENT REPORTS DUTREBIS (AUTHORIZED: HIV INFECTIONS)
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
WHO-VATC QJ05AF05
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
Code System Code Type Description
INN
6908
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
RXCUI
68244
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY RxNorm
CHEBI
63577
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
CAS
134678-17-4
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
FDA UNII
2T8Q726O95
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
LACTMED
Lamivudine
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
LAMIVUDINE
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY Description: A white or almost white powder.Solubility: Soluble in water; sparingly soluble in methanol R; practically insoluble in acetone R. Category: Antiretroviral (Nucleoside Reverse Transcriptase Inhibitor). Storage: Lamivudine should be kept in a well-closed container, protected from light. Additional information: Lamivudine may exhibit polymorphism. Definition: Lamivudine contains not less than 97.0% and not more than 103.0% of C8H11N3O3S, calculated with reference to the dried substance.
MESH
D019259
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
ChEMBL
CHEMBL141
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
NCI_THESAURUS
C1471
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
HSDB
7155
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
USAN
DD-86
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
EPA CompTox
DTXSID7023194
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
WIKIPEDIA
LAMIVUDINE
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
DRUG BANK
DB00709
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
NSC
760061
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
EVMPD
SUB08392MIG
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
MERCK INDEX
M6672
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY Merck Index
DAILYMED
2T8Q726O95
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
PUBCHEM
60825
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
DRUG CENTRAL
1539
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
RS_ITEM_NUM
1356836
Created by admin on Sat Dec 17 18:06:58 UTC 2022 , Edited by admin on Sat Dec 17 18:06:58 UTC 2022
PRIMARY
Related Record Type Details
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
INHIBITOR->TARGET ORGANISM
Structure of LAMIVUDINE METHANOL SOLVATE
SALT/SOLVATE -> PARENT
Structure of LAMIVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of LAMIVUDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 POLYMERASE
TARGET -> INHIBITOR
HEPATITIS B VIRUS
TARGET ORGANISM->INHIBITOR
Related Record Type Details
Structure of LAMIVUDINE SULFOXIDE, (S)-
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of TROXACITABINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 5-(4-AMINO-2-OXOPYRIMIDIN-1(2H)-YL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID, CIS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTOSINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE SULFOXIDE, (R)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE SULFOXIDE, (S)-
IMPURITY -> PARENT
Structure of LAMIVUDINE SULFOXIDE, (R)-
IMPURITY -> PARENT
Structure of URACIL
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of LAMIVUDINE, (±)-TRANS-
IMPURITY -> PARENT
Structure of 1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDINE-2,4(1H,3H)-DIONE, (2R,5S)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of URACIL
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity F. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity F (uracil) about 0.36.
Structure of EMTRICITABINE
PARENT -> IMPURITY
Structure of 5-(4-AMINO-2-OXOPYRIMIDIN-1(2H)-YL)-1,3-OXATHIOLANE-2-CARBOXYLIC ACID, CIS-
IMPURITY -> PARENT
Structure of Salicylic acid
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity C. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity C (salicylic acid) about 2.6. In the chromatogram obtained with solution (1): - the area of any peak corresponding to impurity C is not greater than that of the principal peak in the chromatogram obtained with solution (3) (0.1%).
Structure of 1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDINE-2,4(1H,3H)-DIONE, (2R,5S)-
IMPURITY -> PARENT
Structure of Salicylic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of CYTOSINE
IMPURITY -> PARENT
Structure of CYTOSINE
IMPURITY -> PARENT
Use the chromatogram supplied with lamivudine for system suitability RS and the chromatogram obtained with solutions (4) and (3) to identify the peaks due to impurity F. The impurity peaks are eluted at the following relative retention times with reference to lamivudine (retention time about 11 to 12 minutes): impurity E (cytosine) about 0.31. In the chromatogram obtained with solution (1):- the area of any individual peak corresponding to impurity E, when multiplied by a correction factor of 0.6, is not greater than the area of the peak in the chromatogram obtained with solution (2) (0.1%).
Structure of LAMIVUDINE, (+)-CIS-
IMPURITY -> PARENT
Structure of TROXACITABINE
IMPURITY -> PARENT
Structure of LAMIVUDINE, (±)-TRANS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of URACIL
IMPURITY -> PARENT
Structure of LAMIVUDINE, (+)-CIS-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of Salicylic acid
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LAMIVUDINE SULFOXIDE, (S)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
Structure of LAMIVUDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC Intercellular
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
Elimination
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966